No human-to-human transmission among patients with AES: Study
Kochi: A study based on surveillance data from 17 virus research labs in India found that Nipah virus (NiV) outbreaks in Kerala in 2019, 2021, and 2024 showed no human-to-human transmission among patients with acute encephalitis syndrome (AES).
This was unlike the outbreaks in 2001, 2007, 2018, and 2023, where patients also had acute respiratory distress syndrome (ARDS). The two Nipah spillover events in 2024, where no transmission was observed, highlighted the need for better surveillance of ARDS cases to manage and contain outbreaks, said a recent paper in the Elsevier Journal of Infection and Public Health. The paper stated that India intensified NiV surveillance in West Bengal and Kerala, establishing a network of ten and seven trained virus research and diagnostic laboratories (VRDLs), respectively. Since Nov 2024, these laboratories initiated screening for NiV infection among cases of severe acute respiratory illness (SARI) negative for other common endemic viral respiratory pathogens. This targeted approach helps to identify potential NiV cases early, even when they might be masked by similar illnesses.The study compared the clinical and epidemiological characteristics of AES and ARDS - predominant NiV outbreaks in Kerala to identify factors influencing transmission dynamics and examine public health interventions and their effectiveness in outbreak containment. Researchers from NIV Pune and Kerala, along with the state surveillance unit of the directorate of health services, were involved in the study.It stated that the characteristic coughing and other respiratory symptoms in ARDS patients generate virus-laden aerosols, which, due to their smaller particle size, can travel greater distances and remain suspended in the air for extended periods, increasing the risk of inhalation and subsequent infection. This contrasts sharply with outbreaks where AES predominates, as seen in 2019, 2021, and 2024. Furthermore, the viral load and shedding patterns in AES cases may differ, potentially contributing to reduced transmissibility.The study stated that they found the two NiV outbreaks in Malappuram with AES as the predominant clinical manifestation in July and Sep 2024. Among all close contacts screened, no secondary transmission of NiV was observed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
5 days ago
- The Hindu
State public health lab develops molecular tests to identify deadly amoeba
The State Public Health Laboratory, one of the apex referral laboratories in the State, has developed its own molecular diagnostic test kits to identify five common species of free living amoeba (FLA) which are toxic to humans and which can cause amoebic meningoencephalitis. A highly fatal brain infection, cases of amoebic meningoencephalitis are being reported frequently in Kerala now. 'It was a proud moment for us when we identified Acanthamoeba spp. as the pathogenic organism in one of the acute encephalitis syndrome (AES) samples that we received from the Thiruvananthapuram Government Medical College on Thursday. It was also the first human sample in which we could identify the organism, after we developed the molecular diagnostic test kits six months ago,' says S. Sunija, Director of the State PH Lab. Early identification of the pathogen and treatment are crucial for saving lives when it comes to amoebic meningoencephalitis. Now that the PH lab has developed its own molecular (PCR) assays for identifying the pathogenic organism in human samples, Kerala no longer needs to depend on prime diagnostic facilities outside the State, such as PGI Chandigarh, for confirmatory diagnosis of amoebic meningoencephalitis. Over 400 species Though there are over 400 species of free living amoeba in the environment, only six have been documented to be pathogenic to humans. The State PH lab is also the only lab which has the ability to identify five of these toxic organisms — Naegleria fowleri, Acanthamoeba spp., Vermamoeba vermiformis, Balamuthia mandrillaris and Paravahlkampfia francinae. 'Till now, through the microbiological examination of cerebrospinal fluid samples, we could make only a presumptive diagnosis that it was a trophozoite causing the encephalitis. Naegleria fowleri being the one that causes the most fatal disease, our protocol was to start the patient on the drug cocktail for N. fowleri immediately. But now that the pathogen can be identified and confirmed early, we can optimise the drugs and give targeted treatment to the patient without delay,' says R. Aravind, Head of Infectious Diseases, Government Medical College, Thiruvananthapuram. To labs outside the State Ever since the State began reporting cases of amoebic encephalitis, the lack of confirmatory diagnosis for identifying the causative organism had been a huge challenge. Sending the samples to labs outside the State in proper condition and getting a diagnosis was time consuming. It was when cases began to be reported on a fairly regular basis — especially since the State issued a directive that all AES samples be tested for amoebic encephalitis too — that the State PH lab was assigned the task of developing molecular test kits for identifying the trophozoite. 'Free living amoeba is an ubiquitous organism found in the environment and till Thursday we had been testing only environmental samples. This is the first time we could identify Acanthamoeba in one of the patient samples,' Dr. Sunija says. However, testing water samples from the environment becomes important if the organism found in the human samples is Naegleria fowleri. In that case, the waterbody implicated will have to be tested and public warning issued to avoid it.
Mint
04-06-2025
- Mint
India's drug regulator plans overhaul of Schedule H for prescription medicines
New Delhi: Drugs Controller General of India (DCGI), the country's top drug regulator, is planning a complete overhaul of medicines listed under Schedule H of the Drugs and Cosmetics Rules, 1945, which governs the sale of prescription drugs, said an official aware of the matter and documents reviewed by Mint. Also Read | Key drugs, diagnostics run short in public health centres, govt raises alarm The proposed revamp is driven by concerns, including a rise in antimicrobial resistance (AMR) from self-medication and rampant use of antibiotics purchased over the counter without prescription, the official said. Schedule H includes drugs that cannot be purchased or sold on retail without a doctor's prescription. This overhaul will involve updating the list of prescription drugs by incorporating new medicines and formulations that have been introduced in the market in the recent past. 'The issue related to making suitable reforms in the drug regulatory system has been in discussion for quite some time now. The exercise is part of India's fight against irrational use of antimicrobial medicines, which are used to prevent and treat infectious diseases in humans, animals and plants, including antibiotics, antivirals, antifungals and antiparasitics," said the official on the condition of anonymity. Also Read | What America has got wrong about gender medicine In 2022, a high-level expert committee was constituted by the health ministry to review and revise Schedule H Drugs to recommend comprehensive changes in the drug regulatory regime to reflect global best practices as well as domestic requirements. Remdesivir, dexamethasone, favipiravir, ivermectin and mebrofenin are some of the drugs that are proposed to be added to Schedule H. Right now, there are around 536 drugs under Schedule H. The committee had discussed the existing regulatory framework in detail and noted that the drugs that are not included in Schedule G, H, H1 and X can be easily sold in the country without prescription of a Registered Medical Practitioner (RMP) and it is 'not in public interest", according to the documents reviewed by Mint. Also Read | ICMR gets a breakthrough in attempts to develop first indigenous Nipah virus medicine 'There are many drugs used for various indications like diabetes, TB, heart disease, pain killers etc which are put in special categories like anti-diabetic, anti-pain relief, anti-depressants, anticoagulant drugs, and cardiovascular drugs of the Drug Rule. However, these drugs should fall in schedule H. So, efforts are being made to streamline this," said the official. The expert panel recommended a revamp of the Schedule H. 'Schedule H includes drugs of various categories which require prescription of RMP for their retail sale. The Schedule H needs to be updated regularly to incorporate the new drugs introduced in the market from time to time as well as to review the prescription status of different drugs in the present context. Such regular updates are crucial in the current context to address various regulatory challenges leading to irrational use of drugs, including antibiotics and development of anti-microbial resistance," the documents showed. Wrong or over-use of these medicines can lead to the emergence of antimicrobial resistance (AMR), which is hard to treat and can cause further infections. The committee has proposed more than 700 drugs to be added to the Schedule H drugs list in addition to the existing drugs, as per the documents. The committee also reviewed various aspects of the drugs like their indication, route of administration, international prescription status, abuse or misuse potential, human/ veterinary use, therapeutic/ prophylactic usage etc. When the committee reviewed Schedule G, it opined that drugs mentioned under this list bear caution that 'it is dangerous to take this medicine except under medical supervision". While Schedule G drugs carry a strong caution about medical supervision, the rules governing their sale did not, in the past, explicitly mandate an RMP prescription for every single sale, unlike Schedule H drugs. The committee has recommended the addition of several categories of drugs, namely cardiovascular drugs, neurological drugs, respiratory drugs, anesthetic drugs, antiemetic drugs, immunological drugs, genito-urinary drugs, non-steroidal anti-inflammatory drug, and all sterile formulations of any drug to schedule H.
New Indian Express
04-06-2025
- New Indian Express
Kerala hospitals told to strengthen COVID-19 protocols with more testing
THIRUVANANTHAPURAM: The health department has issued revised guidelines aimed at curbing the spread of Covid, amid a recent spike in cases in the state. The measures include mandatory mask-wearing for high-risk individuals, particularly in crowded public spaces, and renewed emphasis on mask usage, cough etiquette, and hand hygiene. On Tuesday, an 80-year-old man who had tested positive for Covid died. He was also suffering from severe pneumonia and comorbidities. The state reported 19 new Covid cases and one fatality on the same day, bringing the number of active cases to 1,416. The total death toll now stands at nine. Dr Reena K J, director of health services, has directed hospitals to conduct rapid antigen tests for all patients presenting with influenza-like illness (ILI), acute respiratory infections (ARI), or severe acute respiratory infections (SARI). To prevent cross-infection, hospitals must ensure that Covid and influenza patients are accommodated in separate wards or rooms. In healthcare facilities, masks have been made mandatory for all healthcare workers, patients, and visitors. The number of visitors will be limited, and symptomatic individuals will be required to undergo testing before entry. Dr Reena has also urged hospitals to make full use of RT-PCR testing facilities in each district. Additionally, samples with a high viral load (CT value below 25) will be sent to the National Institute of Virology (NIV), Pune, for whole-genome sequencing. Each district is expected to submit at least 15 such samples every two weeks. Hospitals — both public and private — have been instructed to ensure the availability of essential resources, including oxygen supplies, medications, personal protective equipment (PPE), oxygen-supported beds, ventilators, and ICU beds. In relief camps, individuals showing symptoms such as fever, chills, cough, or shortness of breath are required to wear masks. Vulnerable groups — including the elderly, pregnant women, and those with underlying health conditions — are strongly advised to wear masks at all times. Revised guidelines
